Regeneron and Sanofi Cut Price to Compete With Amgen -- Market Talk
May 01 2018 - 9:47AM
Dow Jones News
09:17 ET - Regeneron and Sanofi bet they can jump-start sales of
anti-cholesterol drug Praluent by slashing its price. Express
Scripts, one of the largest prescription drug gatekeepers, is the
first to play ball and agree to ease restrictions on patients
getting the drug. Regeneron and Sanofi said in March they'd offer
to cut the list price of $14,600 annually down to a range of about
$4,500 to $8,000. Express Scripts will pay toward "the lower end"
of that range, Chief Medical Officer Steve Miller tells Dow Jones
in interview. The deal only applies to certain Express Scripts
customers covering about 25 million people; but for those patients,
Praluent will be the exclusive option over Amgen's Repatha.
(joseph.walker@wsj.com; @joewalkerwsj)
(END) Dow Jones Newswires
May 01, 2018 09:32 ET (13:32 GMT)
Copyright (c) 2018 Dow Jones & Company, Inc.
Express Scripts Holding Company (delisted) (NASDAQ:ESRX)
Historical Stock Chart
From Jun 2024 to Jul 2024
Express Scripts Holding Company (delisted) (NASDAQ:ESRX)
Historical Stock Chart
From Jul 2023 to Jul 2024
